Cryoport's 701-Trial Backlog Raises Execution Risk Alarms as Cell Therapy Sector Scales
Cryoport, the dominant cold-chain logistics provider for cell and gene therapies, faces mounting operational pressure as it simultaneously manages 701 active clinical trials and supports 19 commercial therapies. The stakes are uniquely high: a single logistics failure in this space can permanently destroy irreplaceable, patient-specific biologics. Investors and biopharma partners are watching closely as the company's capacity constraints test the limits of specialized supply chain execution.
ViaNews Editorial Team (Finance)•